All stock lists
NovoCure Ltd (NASDAQ:NVCR)
CH · Delayed Price · Currency is USD
Healthcare · Medical - Devices
14.61+1.18 (+8.79%)
Market cap
$1.71B
Insider Score
Health Score
Analyst consensus
Listed since
Oct 2, 2015
Website
Insider Score
––Not scored
NVCR Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
Financial Health Score
Sound
From NVCR’s reported statements · Q3 2026 (trailing 12 months)
Profitability2 / 20
Loses money on what it sells.
- Revenue
- $725.4M
- Net income
- -$121.7M
- Net margin
- -16.8%
Leverage13 / 20
A manageable debt load.
- Total debt
- $231.6M
- Cash
- $96.7M
- Debt / equity
- 0.66
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $673.5M
- Current liabilities
- $270.7M
- Current ratio
- 2.49
Cash generation10 / 20
Roughly cash-neutral.
- Operating cash flow
- $3.6M
- Free cash flow
- -$20.3M
- FCF margin
- -2.8%
Dilution & runway17 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 116.8M
- Share growth (1y)
- 4.4%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
NVCR Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 193.40 M | 183.58 M | 174.06 M | 174.35 M | 167.20 M | 158.81 M |
| Revenue Growth (YoY) | 15.67 % | 15.60 % | 12.30 % | 8.11 % | 7.81 % | 5.62 % |
| Cost of Revenue | 44.53 M | 41.11 M | 38.93 M | 42.16 M | 44.73 M | 41.47 M |
| Gross Profit | 148.87 M | 142.48 M | 135.13 M | 132.19 M | 122.47 M | 117.33 M |
| SG&A Expense | 96.94 M | 101.59 M | 144.21 M | 111.68 M | 104.47 M | 101.02 M |
| R&D Expense | 58.10 M | 51.45 M | 58.34 M | 60.91 M | 54.03 M | 55.83 M |
| Operating Expenses | 155.04 M | 153.04 M | 202.55 M | 172.59 M | 158.50 M | 156.85 M |
| Operating Income | -6.17 M | -10.56 M | -67.42 M | -40.39 M | -36.02 M | -39.52 M |
| Pretax Income | -7.88 M | -12.45 M | -69.26 M | -40.95 M | -30.02 M | -34.98 M |
| Tax Provision | 2.56 M | 3.21 M | 1.88 M | -16.45 M | 7.25 M | 5.16 M |
| Net Income | -10.44 M | -15.66 M | -71.14 M | -24.50 M | -37.27 M | -40.14 M |
| EPS (Basic) | -0.09 | -0.13 | -0.62 | -0.22 | -0.33 | -0.36 |
| EPS (Diluted) | -0.09 | -0.13 | -0.62 | -0.22 | -0.33 | -0.36 |
| Shares Outstanding | 116.79 M | 116.01 M | 114.15 M | 111.47 M | 111.91 M | 111.57 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.